CCL20 and familial pancreatic carcinoma: The results of this manuscript show that CCL20 and its corresponding receptor CCR6 are significantly up-regulated in patients with pancreatic cancer (PCA) and that CCL20 is significantly associated with advanced T-category in those patients.